Healthcare / BiotechnologyStockholm
$32.62
+0.22 (+0.66%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-675.0M · quality 76.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
600.2%
↑Gross Margin
62.4%
↑Debt/Equity
-10.55
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.9%
FCF CAGR
—
FCF margin
-247.1%
FCF / Net income
1.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $222.3M · net income $-534.1M · FCF $-549.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $222.3M | $222.3M | $171.3M | $134.1M | $154.5M |
| Net Income | $-534.1M | $-534.1M | $-807.2M | $-831.7M | $-611.1M |
| EBITDA | $-371.2M | $-371.2M | $-642.1M | $-705.5M | $-554.3M |
| EPS | -6.58 | -6.58 | -12.85 | -15.83 | -13.60 |
| Gross Margin | 62.4% | 62.4% | 51.2% | 52.9% | 75.1% |
| Operating Margin | -233.0% | -233.0% | -368.7% | -590.0% | -372.8% |
| Net Margin | -240.3% | -240.3% | -471.2% | -620.3% | -395.5% |
| Balance Sheet | |||||
| Debt/Equity | -10.55 | -10.55 | -1.83 | -5.16 | 1.31 |
| Current Ratio | 3.63 | 3.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-549.2M | $-549.2M | $-675.0M | $-755.9M | $-506.1M |
| Returns | |||||
| ROE | 600.2% | 600.2% | 136.9% | 495.4% | -101.4% |
| Valuation | |||||
| P/B | — | — | — | — | 4.01 |
| Growth & Yield | |||||
| Revenue Growth | 29.7% | 29.7% | 27.8% | -13.2% | — |
| EPS Growth | 48.8% | 48.8% | 18.8% | -16.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+34.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-12.85 → -6.58
Residual
+34.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.